[Effects of intravenous flecainide acetate in patients with concealed atrioventricular pathway with supraventricular tachycardia].
The acute efficacy and electrophysiologic effects of intravenous flecainide acetate (1.5 mg/kg) on 10 patients with concealed AV pathway with supraventricular tachycardia (SVT) by esophageal programmed electrical stimulation were evaluated. The results showed that: (1) the drug has marked depressing effects on the retrograde accessory pathway conduction and minimal effects on the antegrade AV nodal conduction; (2) there were no effects on the patients with normal sinus node function; (3) the drug has little side effects during the studies; (4) flecainide terminated induced SVT in 9 of 10 cases (90%), and prevented induced SVT in 7 of 9 cases (78%).
Song
Y
Y
Cardiovascular Institute, CAMS, Beijing.
D000328:Adult; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D005424:Flecainide / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D013617:Tachycardia, Supraventricular / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D014927:Wolff-Parkinson-White Syndrome / Q000150:complications
D005424:Flecainide